Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3488 - MERIBEL study: Single-agent eribulin as first-line therapy for taxane-resistant HER2[-] metastatic breast cancer (MBC) patients (pts)


10 Oct 2016


Poster display


Vanesa Ortega


Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365


V. Ortega1, J. Lao2, I. Garau3, N. Afonso4, L. Calvo5, Y. Fernández6, M. Martinez-Garcia7, E. Blanco8, P. Zamora9, M. García10, J.J. Illarramendi11, C. Rodríguez12, E. Aguirre13, J. Pérez14, J. Cortes Castan15, A. Llombart-Cussac16

Author affiliations

  • 1 Medical Oncology, Vall d`Hebron University Hospital Institut d'Oncologia, 08035 - Barcelona/ES
  • 2 Medical Oncology, Hospital Miguel Servet, 50009 - Zaragoza/ES
  • 3 Medical Oncology, Hospital Son Llatzer, 07198 - Palma de Mallorca/ES
  • 4 Medical Oncology, CUF Porto Hospital, Porto/PT
  • 5 Medical Oncology, University Hospital Complex of A Coruña, A Coruna/ES
  • 6 Medical Oncology, Central de Asturias University Hospital, Oviedo/ES
  • 7 Department Of Medical Oncology, University Hospital del Mar, Barcelona/ES
  • 8 Medical Oncology, Hospital Infanta Cristina, Badajoz/ES
  • 9 Medical Oncology, La Paz University Hospital, 28046 - Madrid/ES
  • 10 Medical Oncology, Insular de Las Palmas University Hospital, Las Palmas/ES
  • 11 Medical Oncology, General de Navarra University Hospital, Pamplona/ES
  • 12 Medical Oncology, Clínico de Salamanca Hospital, Salamanca/ES
  • 13 Scientific Department, Medica Scientia Innovation Research, Barcelona/ES
  • 14 Medical Oncology, Institute of Oncology Baselga Quiron Hospital; Medica Scientia Innovation Research MEDSIR ARO, Barcelona/ES
  • 15 Medical Oncology, Ramon y Cajal University Hospital, Madrid and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, 08035 - Barcelona/ES
  • 16 Medical Oncology, Hospital Arnau de Vilanova, Valencia/ES


Abstract 3488


Eribulin improved overall survival (OS) in ≥3 line treatment of MBC pts. In a large retrospective study, short disease-free interval (DFI) and prior taxane therapy have been associated with worse OS in pts receiving first-line chemotherapy for HER2[-] MBC. The aim of MERIBEL trial is to evaluate the efficacy and safety of eribulin as first-line therapy for HER2[-] MBC pts with these poor prognostic factors.


Phase II, multicenter, single arm, trial. Eribulin (1.23 mg/m2) as single-agent was administered on days 1 and 8 of 21 day cycles until progression or unacceptable toxicity. Principal selection criteria: (1) HER2[-] pts without prior chemotherapy for MBC; (2) prior taxane therapy (≥4 cycles) for early BC; (3) less than 36 months* (mo) between the last taxane cycle and relapse; (4) RECIST v1.1 evaluable disease; (5) no symptomatic brain involvement. (*) Amendment to 48 mo. Primary outcome was time to progression (TTP). Secondary endpoints included OS, progression-free survival (PFS), objective response rate (ORR), clinical benefit rate (CBR) and toxicity. We included 53 women from 61 pts recruited between SEP/2013 to MAR/2015 across 12 sites and 2 countries.


Median age 51 years [range 23-83]; 50.9% were ECOG 0; 45.3% were triple-negative; 84.9% received prior anthracyclines. Median DFI was 15.7 mo [0.1-46.5]; and 52.8% had visceral metastases (11.3% with ≥3 involved organ sites). Median follow-up was 12.7 mo [0.2 – 30.5]. Median TTP was 4.1 mo [95%CI 2.2-6], median PFS was 4.3 mo [2.2-6.5], and median OS has not been reached yet. The 1-year TTP, PFS and OS rates were 16.2%, 24.3%, and 65.9%, respectively. The ORR was 20.8% and CBR, 26.4%. Eribulin all grades and 3/4 adverse events (AEs) were reported in 96.2% and 71.7% of the pts, respectively. The most common grade 3/4 AEs were neutropenia (28.3%), leukopenia (17%), peripheral neuropathy (5.7%) and asthenia (5.7%). One patient experienced febrile neutropenia. Percentages of pts with AEs leading to treatment discontinuation, reduction, or delay were 15.1%, 9.4%, and 26.4%, respectively.


Eribulin is effective and safe as first-line therapy for aggressive taxane-resistant HER2[-] MBC pts.

Clinical trial identification

EudraCT: 2012-004463-41

Legal entity responsible for the study

Medica Scientia Innovation Research - MEDSIR ARO




J. Cortes Castan: Javier Cortés has been member on advisory boards of Roche, Celgene, AstraZeneca and Celestial and has received honoraria from Roche, Novartis and Eisai.

A. Llombart-Cussac: Antonio Llombart-Cussac has received honoraria for lectures and advisory boards from Roche, GlaxoSmithKline, Novartis, Celgene, Eisai and AstraZeneca and research funding from GlaxoSmithKline, Sanofi and Puma Biotechnology

All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings